Completed PHASE2 INTERVENTIONAL 2-arm NCT01053949

IFM2009-02-Pomalidomide and Dexamethasone Phase 2 Myeloma (IFM2009-02)

A Multicenter Randomized Open Label Phase II Study of Pomalidomide and Dexamethasone in Relapse and Refractory Multiple Myeloma Patients Who Are Progressive and Did Not Achieve at Least a Partial Response to Bortezomib and Lenalidomide

Sponsor: Celgene Corporation

Conditions Multiple Myeloma

Interventions Pomalidomide

Updated 6 times since 2017 Last updated: Nov 3, 2015 Started: Oct 31, 2009 Primary completion: Apr 30, 2014 Completion: Apr 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Multiple Myeloma, this trial is completed. The trial is conducted by Celgene Corporation and has accumulated 6 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Oct 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Celgene Corporation
University Hospital, Lille

Data source: University Hospital, Lille

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amiens, France , Bobigny, France , Caen, France , Dijon, France , Grenoble, France , Lille, France , Lyon, France , Marseille, France , Nancy, France , Nantes, France and 7 more locations